シェーグレン症候群に伴う口腔乾燥症治療の検討‐セビメリン塩酸塩からピロカルピン塩酸塩への投与変更症例に関して‐

• 目瀬 浩

  岡山大学大学院医歯薬学総合研究科口腔顎顔面外科学分野

• 西山 明慶

  岡山大学大学院医歯薬学総合研究科口腔顎顔面外科学分野

• 佐々木 朗

  岡山大学大学院医歯薬学総合研究科口腔顎顔面外科学分野

書誌事項

タイトル別名

• A clinical study on the effect of dry mouth for patients with Sjoegren's syndrome-Administration was changed from Cevimeline hydrochloride hydrate to pilocarpine hydrochloride-
• —Administration was changed from Cevimeline hydrochloride hydrate to pilocarpine hydrochloride—
• ―セビメリン塩酸塩からピロカルピン塩酸塩への投与変更症例に関して―

抄録

Until recently, Cevimeline hydrochloride hydrate was widely used for dry mouth of patients with Sjögren's syndrome. However, its side effects on the digestive organs may cause patients to reach to loss in quantity of dosage and to discontinue usage. Therefore, we examined the effectiveness and safety of Cevimeline hydrochloride hydrate and Pilocarpine hydrochloride.<br>Subjects: Nine patients (females, aged 46 to 81 years, average age 63.9) diagnosed as Sjögren's syndrome and receiving the medication of Cevimeline hydrochloride hydrate for 2 months or more, were enrolled in this study.<br>Evaluation method: Cevimeline hydrochloride hydrate was modified to Pilocarpine hydrochloride, and stimulated saliva flow values, subjective symptoms, drug tolerance, and side effects were compared. In addition, the quantity of drug administered was adjusted by taking into consideration the number of times by the tolerability.<br>Result: Before the treatment, at the time of Cevimeline hydrochloride hydrate dosage and at the time of Pilocarpine hydrochloride dosage, the stimulated saliva flow values were 4.56 ± 1.81 ml/10 min, 6.07 ± 2.82 ml/10 min and 6.54 ± 2.56 ml/10 min, respectively. As for side effects, Cevimeline hydrochloride hydrate caused various digestive organ conditions, and loss in quantity of dosage was recognized in 3 patients. On the other hand, Pilocarpine hydrochloride showed few side effects, and no patients discontinued the dosage, and no loss in quantity of dosage was observed. Pilocarpine hydrochloride strongly improved subjective and objective symptoms in comparison with Cevimeline hydrochloride hydrate.

収録刊行物

• 歯科薬物療法

  歯科薬物療法 28 (3), 124-129, 2009

  日本歯科薬物療法学会

キーワード

• シェーグレン症候群
• 口腔乾燥
• セビメリン塩酸塩
• ピロカルピン塩酸塩

詳細情報

• CRID: 1390001204733019264
• NII論文ID: 10026132556
• NII書誌ID: AN0023517X
• DOI: 10.11263/jsotp.28.124
• ISSN: 18844928
• ISSN: 02881012
• Web Site: https://search.jamas.or.jp/link/ui/2010138868
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可